BiotechTube

MCY-M11 + Cyclophosphamide

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peritoneal Mesothelioma

Conditions

Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma

Trial Timeline

Aug 27, 2018 → Aug 24, 2021

NCT ID
NCT03608618

About MCY-M11 + Cyclophosphamide

MCY-M11 + Cyclophosphamide is a phase 1 stage product being developed by MaxCyte for Peritoneal Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03608618. Target conditions include Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary.

What happened to similar drugs?

3 of 7 similar drugs in Peritoneal Mesothelioma were approved

Approved (3) Terminated (1) Active (4)
✅ertapenemMerckApproved
✅Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
✅Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄PA21Kissei PharmaceuticalPhase 3
🔄Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03608618Phase 1Terminated

Competing Products

20 competing products in Peritoneal Mesothelioma

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
R744 + R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AbemaciclibEli LillyPhase 1
36
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)AbbViePhase 1/2
32
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLDAstraZenecaPhase 2
35
Tremelimumab + OlaparibAstraZenecaPhase 1
21
ertapenemMerckApproved
43
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + PlaceboNovartisPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2PfizerPhase 1/2
24
Bevacizumab + Nivolumab + RucaparibBristol Myers SquibbPhase 2
39
IniparibSanofiPhase 2
35
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
40
nanoliposomal irinotecanIpsenPhase 1
26
Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
32
Anti-Adhesion ProductBaxterPhase 2
32
PioglitazoneBaxterPre-clinical
23
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
47
RadspherinOncoinventPhase 2
32